LT - Vėžio gydymo būdas, panaudojant imuninio kontrolinio taško inhibitorių; antikūnas, kuris prisiriša prie užprogramuotos mirties 1 receptoriaus (PD-1) arba prie užprogramuotos mirties ligando 1 (PD-L1)
EN - METHOD OF TREATING CANCER USING IMMUNE CHECKPOINT INHIBITOR; ANTIBODY THAT BINDS TO PROGRAMMED DEATH-1 RECEPTOR (PD-1) OR PROGRAMMED DEATH LIGAND 1 (PD-L1)
Legal status
Patent revoked (after opposition at EPO)
Bibliographic data
Indications of the International Patent Classification (IPC)
| (51) |
INT.CL. |
C07K 16/28 |
(2006.01) |
|
|
A61K 39/395 |
(2006.01) |
|
|
G01N 33/574 |
(2006.01) |
|
|
C12Q 1/6886 |
(2018.01) |
|
|
A61K 39/00 |
(2006.01) |
|
|
A61P 35/00 |
(2006.01) |
|
|
C12Q 1/70 |
(2006.01) |
European patent
| (11) |
Number of the document |
3322731 |
| (13) |
Kind of document |
T |
| (96) |
European patent application number |
16744626.9 |
|
Date of filing the European patent application |
2016-07-14 |
| (97) |
Date of publication of the European application |
2018-05-23 |
| (45) |
Date of publication and mention of the grant of the patent |
2021-01-13
|
| (46) |
Date of publication of the claims translation |
2021-03-25
|
PCT application
| (86) |
Number |
PCT/US2016/042297 |
|
Date |
2016-07-14 |
PCT application publication
| (87) |
Number |
WO 2017/011666 |
|
Date |
2017-01-19 |
Priority applications
| (30) |
Number |
Date |
Country code |
|
201562192396 P |
2015-07-14
|
US |
Inventors
| (72) |
MANEKAS, Demetrios, US
GROSSO, Joseph, US
ANDERSON, Jeffrey, US
|
Grantee
| (73) |
Bristol-Myers Squibb Company,
Route 206 and Province Line Road, Princeton, NJ 08543,
US
|
Attorney or representative
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
Title
| (54) |
Vėžio gydymo būdas, panaudojant imuninio kontrolinio taško inhibitorių; antikūnas, kuris prisiriša prie užprogramuotos mirties 1 receptoriaus (PD-1) arba prie užprogramuotos mirties ligando 1 (PD-L1) |
| |
METHOD OF TREATING CANCER USING IMMUNE CHECKPOINT INHIBITOR; ANTIBODY THAT BINDS TO PROGRAMMED DEATH-1 RECEPTOR (PD-1) OR PROGRAMMED DEATH LIGAND 1 (PD-L1) |
Last renewal fee
|
Payment date |
Validity (years) |
Amount |
|
2025-06-04 |
10 |
231.00
EUR
|
Legal status
|
Patent revoked (after opposition at EPO)
|
|
|
Invalidation date |
2026-01-28 |
